



PENDING

(IN202311042999)

**Surface-modified 3-acetyl-11-keto- $\beta$ -boswellic acid (akba)- loaded lyotropic liquid crystalline nanoparticles (lcnps) for topical treatment of rheumatoid arthritis**



## NEED

Rheumatoid arthritis (RA) treatments are limited by side effects and poor efficacy. The need for localized, sustained-release therapies that target specific sites in RA is pressing for better patient outcomes.

## TECHNOLOGY OVERVIEW

This invention introduces surface-modified 3-Acetyl-11-keto- $\beta$ -boswellic acid (AKBA)-loaded lyotropic liquid crystalline nanoparticles (LCNPs) for topical RA treatment. The technology enhances targeting, release control, and bioavailability, offering a promising solution for RA management through transdermal delivery.

## TECHNOLOGY KEY FEATURES

AKBA-loaded LCNPs, particle size <150 nm, entrapment efficiency >65%, targeting agents (hyaluronic acid/chondroitin sulfate), sustained release over 72 hours, transdermal patch or microneedle delivery.

[Read more here](#)

## MARKET ANALYSIS

The global rheumatoid arthritis therapeutics market is expected to grow at a CAGR of 5.2%, reaching \$58.4 billion by 2033 (source: GlobalData, 2023). The global transdermal drug delivery market is anticipated to grow at a CAGR of 7.9%, reaching \$10.4 billion by 2033 (source: Market Research Future, 2024).

## Target Industries

Pharmaceutical companies specializing in arthritis treatments, drug delivery system innovators, research institutes focused on transdermal drug delivery. , Drug delivery system providers, nanoparticle formulation developers, pharmaceutical R&D labs focusing on autoimmune diseases.

## AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

